ANALYSIS OF PNEUMOCOCCAL VACCINATION EFFICACY AND SAFETY IN CHILDREN WITH VARIOUS DISABILITIES OF HEALTH
https://doi.org/10.15690/pf.v9i2.238
Abstract
The results of vaccination tolerability assessment against pneumococcal infection in children with various disabilities of health as well as the results of the follow-up of the vaccinated children are cited. The work was carried out at the Vaccination Department of the Scientific Centre for Children’s Health, RAMS. It is shown that vaccination against pneumococcal infection was safe as in healthy and in children with various disabilities of health. In the post-immunization period there were no serious adverse events observed (frequency of the expressed general and local postvaccinal reactions didn’t exceed 3%). The health of children one year after vaccination remained stable for the underlying disease (if any). It was proved that there was a significant reduction in acute respiratory infections in a group of sickly children, compared with the previous year.
About the Authors
A. G. Gaivoronskaya
Scientific Center of Children’s Health, RAMS, Moscow
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Center of Children’s Health, RAMS, Moscow
I.M. Sechenov First Moscow State Medical University
N.I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
M. G. Galitskaya
Scientific Center of Children’s Health, RAMS, Moscow
Russian Federation
Russian Federation
T. A. Grechukha
Scientific Center of Children’s Health, RAMS, Moscow
Russian Federation
Russian Federation
N. E. Tkachenko
Scientific Center of Children’s Health, RAMS, Moscow
Russian Federation
Russian Federation
M. I. Ivardava
Scientific Center of Children’s Health, RAMS, Moscow
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Tatochenko V.K. Vaccine / ed. V.K. Tatochenko, N. Ozeretskovsky, A. Fedorov. Moscow, 2009. 219p.
2. Kozlov R.S. Pneumococci: past, present and future. 2005. p. 20-21, 26-28.
3. Fedoseenko M.V. The prospect of pneumococcal vaccination: a modern approach to the problem. Breast cancer. 2009, 17 (1): 36-42.
4. Kostinov M.P. Vaccinational prevention of pneumococcal infection and influenza in autoimmune diseases. Guidelines for doctors. Moscow, 2009. p.183-207.
5. Djuretic T., Ryan M.J., Miller E. et al. Hospital admissions in children due to pneumococcal pneumonia in England. J. Infect. 1998; 37: 54–58.
6. Baraff L.J., Lee S.I., Schriger D.L. Outcomes of bacterial meningitis in children a meta-analysis. Pediatr Infect Dis J. 1993; 12: 389-394.
7. Mayansky N.A., Grechukha T.A., Zubkov I.V. et al. The level of antipneumococc antibodies and its dynamics after immunization with pneumococcal polysaccharide vaccine in children having nephrotic syndrome. Diagnostic issues in pediatrics. 2011, 3 (3): 42-46.
8. Bogaert D., De Groot R., Hermans P.W. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004; 4: 144–154.
9. Mayansky A.N. Streptococci: microbiology and pathology. Diagnostic issues in pediatrics. 2010, 2 (2): 9-19.
10. Baranov A.A., Namazov L.S., V.K. Tatochenko. Pneumococcal disease and related disorders is a serious problem of modern health care. Pediatric pharmacology. 2008, 5 (2): 7-12.
11. Mayansky N.A., Alyabiev N.M., L.K. Katosova et al. The definition of capsular serotypes by using multiplex PCR vaccine. Diagnostic issues in pediatrics. 2010; 2 (6): 6-10.
12. Lopukhov L.V., M.V. Edelstein. Polymerase chain reaction in clinical microbiological diagnostics. Clinical Microbiology and Antimicrobial Chemotherapy. 2000, 2 (3): 96-106.
13. Roux A., Schmidt N., Rose M. et al. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir Med. 2004; 98: 1187–1194.
14. Harith S. Preventive vaccination: problems and prospects. Journal Infectology. 2009, 1 (1): 61-65
15. Garin E.H., Barrett D.J. Pneumococcal polysaccharide immunization in patients with active nephrotic syndrome. Nephron. 1988; 50: 383–388.
16. Tejani A., Fikrig S., Schiffman G., Gurumurthy K. Persistence of protective pneumococcal antibody following vaccination in patients with the nephrotic syndrome. Am J Nephrol. 1984; 4: 32–37.
17. Robinson K.A., Baughman W., Rothrock G. et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: opportunities for prevention in the conjugate vaccine era. Jama. 2001; 285: 1729–1735.
18. Revathi R. Ramani, William N. Hall. Impact of PSV7 on invasive pneumococcal disease among children younger than 5 years: A population-based study. American Journal of Public Health. 2004; 94 (6): 958-959.
19. Black S., Shinefield H. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J. 2004; 23 (6): 485-489.
20. Gayvoronskaya A.G., V.V. Botvineva. Follow-up surveillance of children vaccinated against Haemophilus influenzae type b. Pediatric pharmacology. 2010, 7 (3): 18-21.
21. Kostinov M.P., Pakhomov D.V., Korovkina T.I., Andreeva N.P. Pharmacoeconomic impact of vaccination against pneumococcal and Haemophilus influenzae type B infection. Vaccination. News vaccination. 2009, 2 (58): 7-9.
Review
For citations:
Gaivoronskaya A.G., Namazova-Baranova L.S., Galitskaya M.G., Grechukha T.A., Tkachenko N.E., Ivardava M.I. ANALYSIS OF PNEUMOCOCCAL VACCINATION EFFICACY AND SAFETY IN CHILDREN WITH VARIOUS DISABILITIES OF HEALTH. Pediatric pharmacology. 2012;9(2):10-14. https://doi.org/10.15690/pf.v9i2.238
Views:
846
Email this article 